Carla Grandori, PHD, MD

Dr. Carla Grandori is a physician scientist who received her MD from the University of Rome, PhD from the Rockefeller University, and post-doctoral training at MIT. Technology generated by her laboratory at the Fred Hutchinson Cancer Research Center in partnership with co-founders formed the basis of SEngine Precision Medicine. Dr. Grandori leads the company as CEO and CSO, and has developed the PARIS® Test, a next generation, functional diagnostic assay that goes beyond genotypic approaches for precision medicine. It is CLIA certified, available to oncologists across the US, and currently in use at several major cancer centers.

The PARIS® Test is also used as a platform to accelerate drug development, applied to novel gene targets as synthetic lethal partners for the major cancer genes MYC, KRAS and TP53. With the support of a strong management team, Dr. Grandori has advanced several pharma partnerships and financing steps, and the company is now launching a Series B round.